Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Evidence 179635
version: 6; Last updated: 2024-05-16 17:39:42+0000
Profile: ComparativeParticipantFlowEvidence
url: https://fevir.net/resources/Evidence/179635
identifier: FEvIR Object Identifier/179635
name: ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial
title: ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Brian S. Alper:
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparativeParticipantFlowEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | Citation | ResourceReference |
| Cite As | ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635. | |
| Derived From | 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal |
description:
Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial
variableDefinition
description:
Participants in the opioid detoxification trial
variableRole: Population
variableDefinition
description:
GroupAssignment: Lofexidine vs. Placebo
variableRole: Exposure
comparatorCategory: false
variableDefinition
description:
Dropout due to stopping intervention
variableRole: Outcome
observed: PartiicipantFlowMeasure: Dropout due to stopping intervention
statistic
description:
18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)
statisticType: Risk Ratio
quantity: 1.59
numberAffected: 30
SampleSizes
NumberOfParticipants 68 AttributeEstimates
Description Type Quantity p < 0.01
P-value <0.01
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change